Foldax has announced that the Drugs Controller General of India (DCGI), India’s regulatory body for medical devices, has approved initiation of a clinical trial of the Tria biopolymer surgical aortic heart valve.
The Tria valve combines the company’s proprietary biopolymer—LifePolymer—with a design intended to resist calcification and restore patient quality of life without lifelong use of anticoagulants.
The trial will study the ability of the TRIA biopolymer aortic valve to surgically treat patients with aortic valve disease and lead to commercial approval in India.
“After promising outcomes from our US early feasibility study, we are excited to expand our clinical study of the Tria biopolymer valve globally, beginning in India. This study is the first step to commercialising our device outside of the USA,” said Frank Maguire, chief executive officer of Foldax. “Our platform technology is well suited to one of the largest heart valve replacement markets in the world that has relied on mechanical heart valves to treat both aortic and mitral disease. The Tria valves are designed to be uniquely durable while sparing patients from the negative consequences of blood thinning medication. Additionally, our robotic manufacturing process allows us to consider in-country manufacturing with the same precision and quality as our USA-based manufacturing.”
The Tria heart valve is for investigational use only and is not available for commercial sale.
Source CardiovascularNews
Duc Tin Clinic
Tin tức liên quan
Performance diagnostique de l’interféron gamma dans l’identification de l’origine tuberculeuse des pleurésies exsudatives
A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease.
Radiological Approach to Asthma and COPD-The Role of Computed Tomography.
Significant annual cost savings found with UrgoStart in UK and Germany
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389